Trial Profile
Bioabsorbable Vascular Solutions First in Man Clinical Investigation: A Clinical Evaluation of the Bioabsorbable Vascular Solutions Everolimus Eluting Coronary Stent System (BVS EECSS) in the Treatment of Patients With Single de Novo Native Coronary Artery Lesions
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Nov 2018
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms ABSORB-A
- Sponsors Abbott Vascular
- 04 Sep 2013 Results from imaging outcomes at 5 years presented at the ESC Congress 2013: Annual Congress of the European Society of Cardiology.
- 15 Feb 2013 New trial record
- 24 Mar 2009 2-year results summarised in an Abbott media release. Recruitment of ABSORB B has now commenced.